Monoclonal anti-IL-1RAcP antibodies

Patent metadata

Field	Value
Publication number	US-12240898-B2
Application number	US-202117522600-A
Country	US
Kind code	B2
Filing date	Nov 9, 2021
Priority date	Jun 26, 2015
Publication date	Mar 4, 2025
Grant date	Mar 4, 2025

Abstract

Monoclonal antibody that specifically binds IL-1RAcP, or an antigen binding fragment thereof, comprising:
a) a heavy chain variable region (VH) comprising CDR1H, CDR2H and/or CDR3H, wherein the CDR1H region comprises an amino acid sequence selected from the group of SEQ ID NO: 155-231, wherein the CDR2H region comprises an amino acid sequence selected from the group of SEQ ID NO: 232-308, and wherein the CDR3H region comprises an amino acid sequence selected from the group of SEQ ID NO: 309-385; and b) a light chain variable region (VL) comprising CDR1L, CDR2L and/or CDR3L, wherein the CDR1L region comprises an amino acid sequence selected from the group of SEQ ID NO: 386-462, wherein the CDRL2 region comprises an amino acid sequence selected from the group of SEQ ID NO: 463-539, and wherein the CDR3L region comprises an amino acid sequence selected from the group of SEQ ID NO: 540-616

The monoclonal antibody is characterized in that it inhibits IL-1RAcP induced NFkB activity, useful in treatment of IL-1RAcP related diseases.

First claim

The invention claimed is:

1. A monoclonal antibody, or antigen binding fragment thereof, that specifically binds to human IL-1RAcP, wherein the monoclonal antibody or antigen binding fragment thereof comprises:
a heavy chain variable (VH) region comprising the CDR1H region of SEQ ID NO: 158, the CDR2H region of SEQ ID NO: 235 and the CDR3H region of SEQ ID NO: 312, and
a light chain variable (VL) region comprising the CDR1L region of SEQ ID NO: 389, the CDR2L region of SEQ ID NO: 466 and the CDR3L region of SEQ ID NO: 543.

2. The monoclonal antibody, or antigen binding fragment thereof, of claim 1 , wherein ADCC activity of the antibody is reduced by at least 20% relative to an antibody comprising a wild-type human IgG1 Fc region.

3. The monoclonal antibody, or antigen binding fragment thereof, of claim 1 , wherein the antibody has reduced affinity to the human FcγRIIIA, FcγRIIA, and/or FcγRI relative to an antibody comprising a wild-type human IgG1 Fc region.

4. The monoclonal antibody, or antigen binding fragment thereof, of claim 1 , comprising amino acid substitutions at L234A and L235A of the human IgG1 Fc region, or S228P and L235E of the human IgG4 Fc region.

5. The monoclonal antibody, or antigen binding fragment thereof, of claim 1 , comprising a heavy chain variable (VH) region that is at least 90% identical to the VH region of SEQ ID NO: 4.

6. The monoclonal antibody, or antigen binding fragment thereof, of claim 1 , comprising a light chain variable (VL) region that is at least 90% identical to the VL region of SEQ ID NO: 81.

7. The monoclonal antibody, or antigen binding fragment thereof, of claim 1 , comprising the VH region amino acid sequence of SEQ ID NO:4.

8. The monoclonal antibody, or antigen binding fragment thereof, of claim 1 , comprising the VL region amino acid sequence of SEQ ID NO: 81.

9. The monoclonal antibody, or antigen binding fragment thereof, of claim 1 , comprising the VH region of SEQ ID NO:4, and comprising the VL region of SEQ ID NO: 81.

10. The monoclonal antibody, or antigen binding fragment thereof, of claim 1 , comprising a rabbit/human chimeric antibody, or antigen binding fragment thereof.

11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the monoclonal antibody, or antigen binding fragment thereof, of claim 1 .

12. The monoclonal antibody, or antigen binding fragment thereof, of claim 1 , comprising a humanized antibody, or antigen binding fragment thereof.

13. The monoclonal antibody, or antigen binding fragment thereof, of claim 1 , comprising a human IgG1 Fc region.

14. The monoclonal antibody, or antigen binding fragment thereof, of claim 1 , comprising a human IgG4 Fc region.

Assignees

• Sanofi Biotechnology SAS
• Sanofi Biotechnology

Inventors

• Fischer Stephan
• Brandt Michael

Classifications

• C12N5/12

  Fused cells, e.g. hybridomas · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• C07K2317/20

  characterized by taxonomic origin · CPC title